Marimed (MRMD) Income from Non-Controlling Interests (2016 - 2026)
Marimed (MRMD) posted quarterly Income from Non-Controlling Interests of $18000.0 for Q1 2026, down 43.75% year-over-year from $32000.0 in Q1 2025, and up 280.0% quarter-over-quarter from -$10000.0 in Q4 2025.
Marimed (MRMD) Income from Non-Controlling Interests (2016 - 2026) Analysis & Trends
Marimed (MRMD) has reported Income from Non-Controlling Interests for 11 consecutive years, with $18000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 43.75% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $14000.0 (down 77.78% YoY), while the FY2025 annual figure was $28000.0, down 24.32% from the prior year.
- Income from Non-Controlling Interests improved to $18000.0 in Q1 2026 per MRMD's latest filing, from -$10000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $73000.0 in Q2 2022 and bottomed at -$19000.0 in Q1 2023.
- Historically, Income from Non-Controlling Interests has averaged $14882.4 across 5 years, with a median of $12000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests soared 650.0% — and 2025, when it sank 433.33%.
- Marimed's Income from Non-Controlling Interests stood at $4000.0 in 2022, then jumped by 650.0% to $30000.0 in 2023, then sank by 90.0% to $3000.0 in 2024, then tumbled by 433.33% to -$10000.0 in 2025, then surged by 280.0% to $18000.0 in 2026.
- Business Quant data shows MRMD's Income from Non-Controlling Interests at $18000.0 in Q1 2026, -$10000.0 in Q4 2025, and $7000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Marimed | 30.77 Mn | 22.33 Mn | 16.23 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | -10,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Mar 31, 2023 | -19,000.00 |
| Dec 31, 2022 | 4,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | 53,000.00 |
| Dec 31, 2021 | 110,000.00 |
| Sep 30, 2021 | 103,000.00 |